Insulet Corporation $PODD Shares Bought by KBC Group NV

KBC Group NV raised its holdings in Insulet Corporation (NASDAQ:PODD) by 80.6% in the fourth quarter, Holdings Channel reports. The fund owned 111,502 shares of the medical instruments supplier’s stock after buying an additional 49,757 shares during the period. KBC Group NV’s holdings in Insulet were worth $31,693,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Sage Mountain Advisors LLC raised its holdings in Insulet by 4.6% in the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after acquiring an additional 33 shares during the last quarter. Glenmede Investment Management LP raised its holdings in Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares during the last quarter. Curi Capital LLC raised its holdings in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares during the last quarter. WINTON GROUP Ltd raised its holdings in Insulet by 0.9% in the 3rd quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 37 shares during the last quarter. Finally, PDS Planning Inc raised its holdings in Insulet by 5.1% in the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock valued at $253,000 after acquiring an additional 40 shares during the last quarter.

Insulet Stock Performance

Shares of Insulet stock opened at $201.47 on Friday. Insulet Corporation has a 52 week low of $194.61 and a 52 week high of $354.88. The business’s fifty day simple moving average is $228.27 and its 200-day simple moving average is $276.48. The firm has a market cap of $13.95 billion, a PE ratio of 57.56, a price-to-earnings-growth ratio of 1.21 and a beta of 1.47. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. During the same quarter in the prior year, the company posted $1.15 EPS. The company’s quarterly revenue was up 31.2% on a year-over-year basis. Equities analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Michael R. Minogue bought 2,030 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PODD. TD Cowen downgraded shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price objective for the company. in a report on Monday, January 26th. The Goldman Sachs Group cut their price objective on shares of Insulet from $326.00 to $277.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Zacks Research downgraded shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. cut their price target on shares of Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a report on Thursday, February 19th. Nineteen equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $334.38.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.